Back to top
more

Nurix Therapeutics (NRIX)

(Delayed Data from NSDQ)

$24.47 USD

24.47
618,504

-0.11 (-0.45%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $24.50 +0.03 (0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for NRIX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Nurix Therapeutics, Inc falls in the month of November.

All items in Millions except Per Share data.

11/30/2023 11/30/2022 11/30/2021 11/30/2020 11/30/2019
Assets          
Cash & Equivalents 288 309 296 281 38
Receivables 0 0 6 4 0
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 8 9 9 13 2
Total Current Assets 296 318 311 298 39
Net Property & Equipment 17 17 11 7 4
Investments & Advances 7 64 137 91 1
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 5 5 3 0 0
Total Assets 356 417 477 396 44
Liabilities & Shareholders Equity 11/30/2023 11/30/2022 11/30/2021 11/30/2020 11/30/2019
Notes Payable 0 0 0 0 0
Accounts Payable 6 5 7 3 2
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 25 22 15 8 5
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 48 38 41 33 10
Total Current Liabilities 87 71 66 45 16
Mortgages 0 0 0 0 0
Deferred Taxes/Income 45 36 59 61 36
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 1 2
Minority Interest (Liabilities) 0 0 0 0 48
Total Liabilities 155 113 134 106 102
Shareholders Equity 11/30/2023 11/30/2022 11/30/2021 11/30/2020 11/30/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 746 709 564 394 3
Retained Earnings -545 -401 -221 -104 -60
Other Equity -1 -4 -1 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 200 304 342 290 -58
Total Liabilities & Shareholder's Equity 356 417 477 396 44
Total Common Equity 200 304 342 290 -58
Shares Outstanding 48.50 47.10 44.60 38.80 NA
Book Value Per Share 4.13 6.45 7.67 7.48 0.00

Fiscal Year End for Nurix Therapeutics, Inc falls in the month of November.

All items in Millions except Per Share data.

8/31/2024 5/31/2024 2/29/2024 11/30/2023 8/31/2023
Assets          
Cash & Equivalents 448 443 244 288 259
Receivables 0 0 0 0 2
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 8 7 7 8 7
Total Current Assets 456 450 251 296 268
Net Property & Equipment 17 19 18 17 17
Investments & Advances 9 9 10 7 10
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 4 4 4 5 5
Total Assets 514 511 313 356 308
Liabilities & Shareholders Equity 8/31/2024 5/31/2024 2/29/2024 11/30/2023 8/31/2023
Notes Payable 0 0 0 0 0
Accounts Payable 4 3 6 6 2
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 28 23 28 25 22
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 48 47 46 48 32
Total Current Liabilities 86 81 88 87 61
Mortgages 0 0 0 0 0
Deferred Taxes/Income 30 39 34 45 10
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 137 140 144 155 74
Shareholders Equity 8/31/2024 5/31/2024 2/29/2024 11/30/2023 8/31/2023
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 1,057 1,002 756 746 738
Retained Earnings -680 -631 -587 -545 -503
Other Equity 0 0 0 -1 -1
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 377 371 169 200 234
Total Liabilities & Shareholder's Equity 514 511 313 356 308
Total Common Equity 377 371 169 200 234
Shares Outstanding 64.40 64.30 49.10 48.50 48.20
Book Value Per Share 5.85 5.77 3.44 4.13 4.85